Replies to post #86239 on Biotech Values

[DewDiligence]

BMY re Erbitux:

but at the time everyone thought they overpaid and in fact in the end it was profitable.

Has Ertbitux achieved a return on investment that exceeds BMY’s internal threshold for dealmaking? Inasmuch as BMY gets less than half of the profits from US sales of Erbitux and the drug has not been approved for NSCLC, I think the answer is probably No.